Literature DB >> 16272493

Population structure and properties of Candida albicans, as determined by multilocus sequence typing.

Arianna Tavanti1, Amanda D Davidson, Mark J Fordyce, Neil A R Gow, Martin C J Maiden, Frank C Odds.   

Abstract

We submitted a panel of 416 isolates of Candida albicans from separate sources to multilocus sequence typing (MLST). The data generated determined a population structure in which four major clades of closely related isolates were delineated, together with eight minor clades comprising five or more isolates. By Fisher's exact test, a statistically significant association was found between particular clades and the anatomical source, geographical source, ABC genotype, decade of isolation, and homozygosity versus heterozygosity at the mating type-like locus (MTL) of the isolates in the clade. However, these associations may have been influenced by confounding variables, since in a univariate analysis of variance, only the clade associations with ABC type and anatomical source emerged as statistically significant, providing the first indication of possible differences between C. albicans strain type clades and their propensity to infect or colonize different anatomical locations. There were no significant differences between clades with respect to distributions of isolates resistant to fluconazole, itraconazole, or flucytosine. However, the majority of flucytosine-resistant isolates belonged to clade 1, and these isolates, but not flucytosine-resistant isolates in other clades, bore a unique mutation in the FUR1 gene that probably accounts for their resistance. A significantly higher proportion of isolates resistant to fluconazole, itraconazole, and flucytosine were homozygous at the MTL, suggesting that antifungal pressure may trigger a common mechanism that leads both to resistance and to MTL homozygosity. The utility of MLST for determining clade assignments of clinical isolates will form the basis for strain selection for future research into C. albicans virulence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272493      PMCID: PMC1287804          DOI: 10.1128/JCM.43.11.5601-5613.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  48 in total

1.  Non-identity and authentication of two major reference strains of Candida albicans.

Authors:  D W MacKenzie; F C Odds
Journal:  J Med Vet Mycol       Date:  1991

2.  Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus.

Authors:  T C White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  Detection of amphotericin B-resistant Candida isolates in a broth-based system.

Authors:  J H Rex; C R Cooper; W G Merz; J N Galgiani; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

4.  Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

Authors:  S Redding; J Smith; G Farinacci; M Rinaldi; A Fothergill; J Rhine-Chalberg; M Pfaller
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

5.  Comparative analysis of genetic variability among Candida albicans isolates from different geographic locales by three genotypic methods.

Authors:  K V Clemons; F Feroze; K Holmberg; D A Stevens
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

6.  Prevalence of Candida dubliniensis isolates in a yeast stock collection.

Authors:  F C Odds; L Van Nuffel; G Dams
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

7.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Authors:  D Sanglard; K Kuchler; F Ischer; J L Pagani; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

8.  Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation.

Authors:  F C Odds; L Vranckx; F Woestenborghs
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

9.  Physiological traits associated with success of Candida albicans strains as commensal colonizers and pathogens.

Authors:  J Schmid; P R Hunter; G C White; A K Nand; R D Cannon
Journal:  J Clin Microbiol       Date:  1995-11       Impact factor: 5.948

10.  Long-term laboratory preservation of pathogenic yeasts in water.

Authors:  F C Odds
Journal:  J Med Vet Mycol       Date:  1991
View more
  80 in total

1.  Multilocus sequence typing for analyses of clonality of Candida albicans strains in Taiwan.

Authors:  Kuo-Wei Chen; Yee-Chun Chen; Hsiu-Jung Lo; Frank C Odds; Tzu-Hui Wang; Chi-Yang Lin; Shu-Ying Li
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  TOS9 regulates white-opaque switching in Candida albicans.

Authors:  Thyagarajan Srikantha; Anthony R Borneman; Karla J Daniels; Claude Pujol; Wei Wu; Michael R Seringhaus; Mark Gerstein; Song Yi; Michael Snyder; David R Soll
Journal:  Eukaryot Cell       Date:  2006-09-01

3.  Molecular phylogenetics of Candida albicans.

Authors:  Frank C Odds; Marie-Elisabeth Bougnoux; Duncan J Shaw; Judith M Bain; Amanda D Davidson; Dorothée Diogo; Mette D Jacobsen; Maud Lecomte; Shu-Ying Li; Arianna Tavanti; Martin C J Maiden; Neil A R Gow; Christophe d'Enfert
Journal:  Eukaryot Cell       Date:  2007-04-06

4.  Molecular and Histological Association Between Candida albicans from Oral Soft Tissue and Carious Dentine of HIV-Positive Children.

Authors:  Elaine Blignaut; Willie F P van Heerden
Journal:  Mycopathologia       Date:  2015-07-08       Impact factor: 2.574

Review 5.  Multilocus sequence typing of pathogenic Candida species.

Authors:  Frank C Odds; Mette D Jacobsen
Journal:  Eukaryot Cell       Date:  2008-05-02

Review 6.  Mechanisms of genome evolution in Candida albicans.

Authors:  Iuliana V Ene; Richard J Bennett; Matthew Z Anderson
Journal:  Curr Opin Microbiol       Date:  2019-06-06       Impact factor: 7.934

7.  Selective Advantages of a Parasexual Cycle for the Yeast Candida albicans.

Authors:  Ningxin Zhang; Beatrice B Magee; Paul T Magee; Barbara R Holland; Ely Rodrigues; Ann R Holmes; Richard D Cannon; Jan Schmid
Journal:  Genetics       Date:  2015-06-10       Impact factor: 4.562

8.  Performance of optimized McRAPD in identification of 9 yeast species frequently isolated from patient samples: potential for automation.

Authors:  Jitka Trtkova; Petr Pavlicek; Lenka Ruskova; Petr Hamal; Dagmar Koukalova; Vladislav Raclavsky
Journal:  BMC Microbiol       Date:  2009-11-10       Impact factor: 3.605

9.  Evolution of pathogenicity and sexual reproduction in eight Candida genomes.

Authors:  Geraldine Butler; Matthew D Rasmussen; Michael F Lin; Manuel A S Santos; Sharadha Sakthikumar; Carol A Munro; Esther Rheinbay; Manfred Grabherr; Anja Forche; Jennifer L Reedy; Ino Agrafioti; Martha B Arnaud; Steven Bates; Alistair J P Brown; Sascha Brunke; Maria C Costanzo; David A Fitzpatrick; Piet W J de Groot; David Harris; Lois L Hoyer; Bernhard Hube; Frans M Klis; Chinnappa Kodira; Nicola Lennard; Mary E Logue; Ronny Martin; Aaron M Neiman; Elissavet Nikolaou; Michael A Quail; Janet Quinn; Maria C Santos; Florian F Schmitzberger; Gavin Sherlock; Prachi Shah; Kevin A T Silverstein; Marek S Skrzypek; David Soll; Rodney Staggs; Ian Stansfield; Michael P H Stumpf; Peter E Sudbery; Thyagarajan Srikantha; Qiandong Zeng; Judith Berman; Matthew Berriman; Joseph Heitman; Neil A R Gow; Michael C Lorenz; Bruce W Birren; Manolis Kellis; Christina A Cuomo
Journal:  Nature       Date:  2009-06-04       Impact factor: 49.962

10.  One year prospective survey of Candida bloodstream infections in Scotland.

Authors:  Frank C Odds; Mary F Hanson; Amanda D Davidson; Mette D Jacobsen; Pauline Wright; Julie A Whyte; Neil A R Gow; Brian L Jones
Journal:  J Med Microbiol       Date:  2007-08       Impact factor: 2.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.